title: [Dacarbazine, a chemotherapeutic against metastatic melanoma and a reference drug for new treatment modalities].
abstract: Melanoma is a tumour derived from melanocytes, cells of neuroectodermal origin. Melanoma treatment represents a challenge to oncologists due to its aggressive course and early and multiple metastases. Surgical excision of lesions is a highly effective intervention, but only in early stages. In contrast, median survival of patients with metastatic melanoma is still below one year. In 2011 the FDA and EMA have approved new drugs, ipilimumab and vemurafenib, that might be a major breakthrough in treating patients with advanced melanoma. However, time is needed to conclude whether they replace dacarbazine, a drug used for over 30 years in the therapy of metastatic melanoma, even if the response rate was only 10-15%. The mechanism of dacarbazine action is not clear but it is probably based on methylation of purine bases in DNA. The low therapeutic efficacy of dacarbazine might be the consequence of rapid removal of DNA lesions by repair systems. A high melanoma chemoresistance is also driven by the extent and nature of alterations in signal transductions in tumour cells. None of the previously conducted trials proved superiority of any treatment modality over monotherapy with dacarbazine. Higher response rates did not correlate with survival benefit, and more intense adverse effects were frequently observed. There are some expectations for targeted therapy and immunotherapy, which have already demonstrated some efficacy in clinical studies. This review aims at providing the current knowledge on dacarbazine and its analogue, temozolomide, including the latest results of clinical studies combining these drugs with other treatment protocols.
authors.affiliation: Zakład Biologii Molekularnej Nowotworów, Uniwersytet Medyczny w Łodzi.
authors.forename: Kamila
authors.initials: K
authors.lastname: Koprowska
authors.forename: Małgorzata
authors.initials: M
authors.lastname: Czyż
mesh_terms: D000911:Antibodies, Monoclonal / Q000737:chemistry / Q000627:therapeutic use*; D018906:Antineoplastic Agents, Alkylating / Q000737:chemistry / Q000627:therapeutic use*; D004249:DNA Damage / Q000187:drug effects; D003606:Dacarbazine / Q000031:analogs & derivatives* / Q000737:chemistry / Q000627:therapeutic use*; D006801:Humans; D007167:Immunotherapy / Q000379:methods; D007211:Indoles / Q000737:chemistry / Q000627:therapeutic use*; D000074324:Ipilimumab; D008545:Melanoma / Q000188:drug therapy*; D016032:Randomized Controlled Trials as Topic; D013449:Sulfonamides / Q000737:chemistry / Q000627:therapeutic use*; D000077204:Temozolomide; D000077484:Vemurafenib
chemical_list: D000911:Antibodies, Monoclonal; D018906:Antineoplastic Agents, Alkylating; D007211:Indoles; D000074324:Ipilimumab; D013449:Sulfonamides; D000077484:Vemurafenib; D003606:Dacarbazine; D000077204:Temozolomide